Virtual Library
Start Your Search
X. Zhao
Author of
-
+
P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.01-076 - Clinical Study of Anti-Angiogenesis Therapy Combined with Neo-Adjuvant Chemotherapy on NSCLC Patients in Phase IIIa (N2) (ID 1347)
09:30 - 09:30 | Author(s): X. Zhao
- Abstract
Background:
This study aimed to explore the safety and effectiveness of anti-angiogenesis agent Endostar combined with neo-adjuvant chemotherapeutic therapy in the treatment of non-small cell lung cancer (NSCLC) patients in phase ⅢA (N2).
Methods:
From April, 2011 to December, 2013, a total of 30 patients diagnosed as NSCLC in phase ⅢA (N2) by pathology or assistant examinations were selected in the randomized, control and open clinical study treated with NP combined with Endostar or single NP neo-adjuvant chemotherapeutic therapy. Control group was treated with neo-adjuvant NP chemotherapy for 2 weeks, on which basis trial group was added with Endostar for 2 weeks. Clinical efficacy was evaluated 3 weeks and surgery was performed within 4 weeks after 2-cycle treatment. The primary end points were response rate (RR), clinical benefit rate (CBR) and tumor regression rate (TRR) as well as peri-operative clinical indexes and safety. The secondary end points included disease-free survival time (DFS) and overall survival time (OS).
Results:
In the 26 patients with evaluable efficacy, trial group and control group were 50.0% and 40.0% in RR (P＝1.0), 87.5% and 64.0% in CBR (P＝0.76), 19.7% and 7.1% in TRR (P＝0.036), 12.0 months and 10.0 months in total DFS (P＝0.44) and 16.0 months and 14.0 months in OS (P＝0.39), respectively. however, there was no significant difference between two groups in all clinical indexes and hematological and non-hematological toxicities in all degrees (P＞0.05).
Conclusion:
Endostar combined with NP chemotherapy are markedly higher than single NP neo-adjuvant chemotherapy in RR, CBR, TRR, DFS and OS without increasing the therapeutic toxicities. In addition, there is no significant difference between two groups in peri-operative clinical indexes, indicating that Endostar combined with NP chemotherapy are safe and effective in treating patients with NSCLC in ⅢA (N2).
